SANGAMO THERAPEUTICS, INC (SGMO) Form 10-Q — May 14, 2026
Sangamo Therapeutics reported a net loss of $31.0 million for Q1 2026, with cash reserves of $27.6 million sufficient only into the third quarter of 2026. Management explicitly stated there is substantial doubt about the company’s ability to continue as a going concern and warned it may seek bankruptcy protection in the very near term if adequate funding is not secured. The company’s common stock was delisted from Nasdaq on May 5, 2026, due to failure to meet minimum bid price requirements, and now trades on the OTCQB Venture Market. Sangamo has requested a hearing to appeal the delisting, scheduled for June 9, 2026, but trading remains suspended on Nasdaq pending the outcome.
Key figures
- Revenue
- 1442000
- Total Debt
- 0
- Cash Position
- 27586000
- Shares Outstanding
- 414288847
- Ga expense q1
- 6818000
- Rd expense q1
- 26570000
- Operating loss q1
- 31946000
- Atm remaining capacity
- 129500000
Price after filing
Close on the filing date to close N calendar days later (from $0.14). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.